---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000045"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:08:27.125040+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Travere Q2 2025: FILSPARI sales $71.9M (+165% YoY); net loss narrows to $12.8M

## Summary
- U.S. FILSPARI net product sales $71.9M, up 165% YoY; 745 new patient start forms received in Q2.
- Total revenue $114.4M including $17.5M milestone from CSL Vifor; net product sales total $94.8M.
- Net loss $12.8M ($0.14/share) vs $70.4M loss ($0.91/share) in Q2 2024; non-GAAP net income $11.9M.
- Cash $319.5M; sNDA for FSGS accepted with PDUFA Jan 13, 2026; IgAN REMS modification PDUFA Aug 28, 2025.
- R&D expense $49.4M (-9% YoY); SG&A expense $76.2M (+18% YoY).

## SEC filing metadata
- accession: 0001438533-25-000045
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/0001438533-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/tvtx-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000045
- JSON: https://secwatch.observer/filing/0001438533-25-000045.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.